08:32 AM EDT, 07/14/2025 (MT Newswires) -- Avalon GloboCare ( ALBT ) said Monday it granted a new standard patent in Hong Kong for its proprietary CAR-T and CAR-Natural Killer cell technology.

The company said the patent for the technology, co-developed with Hong Kong-based partner Arbele, is valid for 20 years, starting Feb. 21, 2020.

The patented technology would boost the production and effectiveness of CAR-T and CAR-NK cell therapies, particularly in fighting blood cancers, the company said.